Evidence map›Paper›PMID 39484542›Full record

ArticlebioRxiv : the preprint server for biology2024

Spatial memory in Alzheimer's disease 5XFAD mice is enhanced by XPO1 inhibitor KPT-330.

Shi Quan Wong, Adia Ouellette, Avery McNamara, Rachel A Tam, Alexander Alexandrov, Acacia Nawrocik-Madrid, Jesus J Sanchez, Brett C Ginsburg, Arturo A Andrade, Louis R Lapierre

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Shi Quan WongDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, 185 Meeting St., Providence, Rhode Island 02912, USA.
Adia OuelletteCentre de Médecine de Précision du Nouveau Brunswick, 27 rue Providence, Moncton, New Brunswick, E1C 8X3, Canada.
Avery McNamaraDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, 185 Meeting St., Providence, Rhode Island 02912, USA.
Rachel A TamDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, 185 Meeting St., Providence, Rhode Island 02912, USA.
Alexander AlexandrovDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, 185 Meeting St., Providence, Rhode Island 02912, USA.
Acacia Nawrocik-MadridNathan Shock Center San Antonio, Analytical Pharmacology and Drug Evaluation Core, University of Texas in San Antonio, San Antonio, TX, USA.
Jesus J SanchezNathan Shock Center San Antonio, Analytical Pharmacology and Drug Evaluation Core, University of Texas in San Antonio, San Antonio, TX, USA.
Brett C GinsburgNathan Shock Center San Antonio, Analytical Pharmacology and Drug Evaluation Core, University of Texas in San Antonio, San Antonio, TX, USA.
Arturo A AndradeDepartment of Neuroscience, Brown University, 185 Meeting St., Providence, Rhode Island 02912, USA.
Louis R LapierreDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, 185 Meeting St., Providence, Rhode Island 02912, USA.ORCID 0000-0002-8154-141X

Funding

TRANSGENIC COREP30AG013319 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI JAMES FLOYD NELSON · 1995 to 2026
$30.6M
CaV2.2 splice variants in the hippocampus: function and pharmacologyR01MH124811 · NIMH · BROWN UNIVERSITY · PI Arturo Andrade · 2022 to 2026
$1.9M
Regulation of the transcription factor HLH-30/TFEB in agingR01AG051810 · NIA · BROWN UNIVERSITY · PI LAPIERRE, LOUIS RENE · 2016 to 2020
$1.9M
Investigating nucleo-cytoplasmic partitioning in Alzheimer's disease and agingR21AG068922 · NIA · BROWN UNIVERSITY · PI LAPIERRE, LOUIS RENE · 2020 to 2021
$437k
NIA NIH HHS P30 AG013319NIA NIH HHS R01 AG051810NIA NIH HHS R21 AG068922NIMH NIH HHS R01 MH124811
6 · The paper itself

Abstract

The proteostatic decline in Alzheimer's disease is well established and improvement in proteostasis could potentially delay cognitive impairment. One emerging entry point to modulate proteostasis is the regulation of nucleo-cytoplasmic partitioning of proteins across the nuclear pore via karyopherins. The nuclear exportin XPO1 is a key regulator of proteostasis by driving the assembly of ribosomes and by modulating the process of autophagy. We recently found that XPO1 inhibitor KPT-330 (Selinexor), an FDA approved drug against multiple myelomas, enhances proteostasis, leading to benefits in models of neurodegenerative diseases in

Identifiers

PMID39484542
PMCPMC11527021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.